Back to top
more

BioRad Laboratories (BIO)

(Real Time Quote from BATS)

$264.36 USD

264.36
221,786

-7.82 (-2.87%)

Updated Aug 6, 2025 03:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Should You Sell Bio-Rad Laboratories (BIO) Before Earnings?

by Zacks Equity Research

Bio-Rad Laboratories (BIO) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

    Zacks Equity Research

    Will Admissions Drive Universal Health's (UHS) Q4 Earnings?

    by Zacks Equity Research

    Solid performances at Acute Care and Behavioral Health segments are likely to boost Universal Health's (UHS) Q4 results.

      Zacks Equity Research

      Cardinal Health Strong on Medical & Pharmaceutical Segments

      by Zacks Equity Research

      Cardinal Health (CAH) gains large number of Pharmaceutical Distribution customers.

        Zacks Equity Research

        Here's Why You Should Invest in LabCorp (LH) Stock Right Now

        by Zacks Equity Research

        Strong guidance and Covance Drug Development's sturdy growth raise investors optimism on LabCorp (LH).

          Zacks Equity Research

          Medtronic (MDT) Unveils MiniMed Mio Advance Infusion Set

          by Zacks Equity Research

          Medtronic (MDT) continues to adopt initiatives to drive the performance of its Diabetes segment.

            Zacks Equity Research

            Integer Holdings (ITGR) Beats on Q4 Earnings, Issues '18 View

            by Zacks Equity Research

            Integer Holdings' (ITGR) fourth-quarter 2017 results benefit from strong performance in its Medical and Non-Medical units.

              Zacks Equity Research

              5 Reasons Why You Should Add Becton, Dickinson (BDX) Now

              by Zacks Equity Research

              Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.

                Zacks Equity Research

                Here's Why You Should Keep Omnicell (OMCL) in Your Portfolio

                by Zacks Equity Research

                Omnicell (OMCL) continues to progress well with its three-legged strategy. However, escalating costs and tough hospital spending trends pose threats.

                  Zacks Equity Research

                  Here's Why You Should Invest in Edwards Lifesciences (EW) Now

                  by Zacks Equity Research

                  Recent buyouts and CE Mark boost investors' confidence in Edwards Lifesciences (EW).

                    Zacks Equity Research

                    Henry Schein (HSIC) Q4 Earnings in Line, 2018 View Upbeat

                    by Zacks Equity Research

                    Henry Schein's (HSIC) strong share gains in the North American and overseas markets along with solid revenues raise optimism.

                      Zacks Equity Research

                      Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                      by Zacks Equity Research

                      IDEXX Laboratories (IDXX) continues to boost investor confidence on strong companion animal business along with growth across all segments.

                        Zacks Equity Research

                        Myriad Genetics Banks on Product Launches, Competition Rife

                        by Zacks Equity Research

                        Myriad Genetics (MYGN) focuses on strengthening the Molecular Diagnostics portfolio through product launches.

                          Zacks Equity Research

                          Abiomed Hits New 52-Week High: 4 Factors Driving the Stock

                          by Zacks Equity Research

                          Abiomed's (ABMD) recent regulatory approvals and raised guidance boost investors' confidence.

                            Zacks Equity Research

                            Edwards Lifesciences' CE Mark for CENTERA Boosts THVT Arm

                            by Zacks Equity Research

                            Edward Lifesciences (EW) witnesses multiple developments in THV segment.

                              Zacks Equity Research

                              Medtronic's Positive Study Results May Expand Customer Base

                              by Zacks Equity Research

                              Medtronic (MDT) leaves no stone unturned to boost the performance of its Diabetes business.

                                Zacks Equity Research

                                Cardiovascular Systems Portfolio Solid, Competition Rife

                                by Zacks Equity Research

                                Cardiovascular Systems (CSII) expands product portfolio to enhance market reach.

                                  Zacks Equity Research

                                  Allscripts (MDRX) Q4 Earnings Meet, Revenues Beat Estimates

                                  by Zacks Equity Research

                                  Solid year-over-year growth in Client Services revenues drove Allscripts in Q4.

                                    Zacks Equity Research

                                    5 Reasons Why You Should Buy CONMED (CNMD) Stock Right Now

                                    by Zacks Equity Research

                                    Strong market trends and share price performance fortify CONMED's (CNMD) foothold in the niche markets.

                                      Zacks Equity Research

                                      GNC Holdings to Boost International Business With New Deals

                                      by Zacks Equity Research

                                      GNC Holdings (GNC) adopts initiatives to boost contributions from international business with strong focus on China.

                                        Zacks Equity Research

                                        Myriad Genetics' Positive Study Data May Expand Customer Base

                                        by Zacks Equity Research

                                        Myriad Genetics (MYGN) leaves no stone unturned to drive the uptake of myRisk Hereditary Cancer test and strengthen the Molecular Diagnostics portfolio.

                                          Zacks Equity Research

                                          Here's Why You Should Sweep Up Quest Diagnostics Right Now

                                          by Zacks Equity Research

                                          Quest Diagnostics' (DGX) latest acquisitions boost investors' confidence.

                                            Zacks Equity Research

                                            Becton, Dickinson Gains on Strong Q1 Results & Acquisitions

                                            by Zacks Equity Research

                                            Acquisition of C.R.Bard and a solid FY18 guidance are key catalysts for Becton, Dickinson (BDX).

                                              Zacks Equity Research

                                              Amedisys (AMED) Strong on Home Health, Margin Decline a Woe

                                              by Zacks Equity Research

                                              Amedisys' (AMED) acquisition of Tenet Healthcare's home health and hospice operations in Arizona might help the company deliver high-quality post-acute services in the key markets.

                                                Zacks Equity Research

                                                Haemonetics (HAE) Banks on Plasma Franchise, Competition Rife

                                                by Zacks Equity Research

                                                Haemonetics' (HAE) strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth.

                                                  Zacks Equity Research

                                                  Abbott's FreeStyle LibreLink App Now Available in Europe

                                                  by Zacks Equity Research

                                                  Abbott (ABT) leaves no stone unturned to cash in on the growing popularity of FreeStyle Libre system that eliminates the need for daily finger sticks.